CPRX Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -49.65%. Catalyst Pharmaceuticals's return on equity of 29.43% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 59.84%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Catalyst Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Catalyst Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.664, which suggesting that the stock is 33.579% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Catalyst Pharmaceuticals's net income of $56.7M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 13.66x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.05x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of 40.56%. Catalyst Pharmaceuticals's return on equity of 29.43% beat United Therapeutics's return on equity of 19.92%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 59.84%. On the other hand United Therapeutics has an analysts' consensus of $377.01 which suggests that it could grow by 26.8%. Given that Catalyst Pharmaceuticals has higher upside potential than United Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than United Therapeutics.

Catalyst Pharmaceuticals has a beta of 0.664, which suggesting that the stock is 33.579% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.629%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Catalyst Pharmaceuticals's net income of $56.7M is lower than United Therapeutics's net income of $322.2M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 13.66x while United Therapeutics's PE ratio is 11.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.05x versus 4.79x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of -147.92%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Xencor's return on equity of -32.34%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 59.84%. On the other hand Xencor has an analysts' consensus of $28.20 which suggests that it could grow by 210.92%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.664, which suggesting that the stock is 33.579% less volatile than S&P 500. In comparison Xencor has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.525%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are larger than Xencor quarterly revenues of $32.7M. Catalyst Pharmaceuticals's net income of $56.7M is higher than Xencor's net income of -$48.4M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 13.66x while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.05x versus 4.86x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 40.12% compared to Catalyst Pharmaceuticals's net margin of 28.42%. Catalyst Pharmaceuticals's return on equity of 29.43% beat Zoetis's return on equity of 51.03%.

Catalyst Pharmaceuticals has a consensus price target of $34.29, signalling upside risk potential of 59.84%. On the other hand Zoetis has an analysts' consensus of $194.10 which suggests that it could grow by 29.37%. Given that Catalyst Pharmaceuticals has higher upside potential than Zoetis, analysts believe Catalyst Pharmaceuticals is more attractive than Zoetis.

Catalyst Pharmaceuticals has a beta of 0.664, which suggesting that the stock is 33.579% less volatile than S&P 500. In comparison Zoetis has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.074%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.24% to investors and pays a quarterly dividend of $0.50 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Catalyst Pharmaceuticals quarterly revenues are $141.4M, which are smaller than Zoetis quarterly revenues of $2.2B. Catalyst Pharmaceuticals's net income of $56.7M is lower than Zoetis's net income of $631M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 13.66x while Zoetis's PE ratio is 26.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.05x versus 7.31x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.